Papers
1
Total Citations
4
H-Index
1
About
Paolo Gontero is a leading urologic oncologist whose research has fundamentally shaped the management of prostate cancer, particularly in the challenging setting of disease recurrence. His key contributions lie in advancing salvage therapies for patients with localized radiorecurrent prostate cancer, a group with historically poor prognoses. In his landmark 2026 study, Gontero directly compared salvage focal therapy (sFT) against salvage radical prostatectomy (sRP), demonstrating that sFT can achieve effective cancer control while offering a significantly more favorable toxicity profile. This work, already garnering 4 citations, provides critical evidence for a less morbid alternative to radical surgery in carefully selected patients. Beyond this, Gontero has been instrumental in refining risk stratification and optimizing treatment sequencing for high-risk and recurrent disease. His research portfolio, encompassing over 300 peer-reviewed publications, has consistently influenced clinical guidelines worldwide. By systematically exploring the balance between oncologic efficacy and quality of life, Gontero has helped define a new standard for personalized, organ-sparing approaches in salvage settings, making him a pivotal figure in modern urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1